Figure 1From: Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancerRelative intratumor ATM mRNA levels among patients with locally advanced breast cancer. (A) ATM mRNA levels among patients receiving neoadjuvant doxorubicin or 5-fluorouracil/mitomycin (n = 69; Cohort 1). Blue bars represent patients displaying stable disease or response to treatment. White bars represent patients with progressive disease (PD) and TP53 or CHEK mutations, while red bars (with arrows) indicate PD-patients with wild-type TP53 and CHEK2. (B) ATM mRNA levels among patients receiving neoadjuvant epirubicin (n = 109; Cohort 2). Color key as for A.Back to article page